We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click ...
StockNews.com cut shares of Elevance Health (NYSE:ELV – Free Report) from a buy rating to a hold rating in a research note ...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a ...
In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Wells Fargo & Company reduced their target price on shares of Elevance Health from $593.00 to $495.00 and set an “overweight” rating on the stock in a report on Monday, November 4th.
With earnings season in full swing, the volume of insider transactions has fallen to seasonal lows, with only 615 transactions meeting the criteria for inclusion in Vickers Weekly Insider Report ...
Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...
Shares of Elevance Health Inc. ELV rose 2.56% to $411.24 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0. ...
Despite a 29% drop in Elevance Health's stock, I maintain a strong buy rating due to a DCF price target of $549.60, indicating 43% upside. ELV's shift towards managed care, with strong industry ...